- Breast-conserving therapy for breast cancer
- The effect of radiation in patients with BRCA-1 or BRCA-2 mutations
- The use of intensity modulated radiotherapy in the treatment of breast cancer
- Indications for post-mastectomy radiotherapy
- The use of radiosensitizers in patients with refractory disease
Pam Reitenga 734-764-9922
Dr. Lori Pierce attended Duke University School of Medicine and completed a Radiation Oncology residency and chief residency at the Hospital of the University of Pennsylvania. She then was appointed as a Senior Investigator at the National Cancer Institute, National Institutes of Health in Bethesda, MD. In 1992, Dr. Pierce joined the faculty of the University of Michigan. Since coming to Michigan, she has served as residency director and clinical director in the Department of Radiation Oncology. In August 2005, Dr. Pierce was appointed by the University of Michigan Board of Regents to be Vice Provost for Academic and Faculty Affairs.
Her research focuses on the use of radiotherapy in the multi-modality treatment of breast cancer, with emphasis on intensity modulated radiotherapy in node positive breast cancer, the use of radiosensitizing agents, and the outcomes of radiation in women with breast cancer who carry a BRCA1/2 breast cancer susceptibility gene. She is also Director of the the Michigan Radiation Oncology Quality Consortium (MROQC), a quality consortium of radiation oncology practices across the state of Michigan that seeks to establish best practices in the treatment of breast and lung cancers. This initiative is funded by Blue Cross Blue Shield of Michigan and Blue Care Network.
Areas of Interest
- Breast cancer
Honors & Awards
2015 Malcolm Bagshaw Visiting Professor, Stanford University
2015 Fellow Inductee, American Society for Clinical Oncology (ASCO)
2013-2017 Listed among Castle Connolly’s “America’s Top Physicians for Cancer”
2013 AAWR Marie Curie Award
2013 League of Educational Excellence Award
2010-2018 Susan G. Komen for the Cure Scholar
2010-Present Member of Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Steering Committee
2010 Sara Goddard Power Award from the American Women’s Caucus
2010 Fellow Inductee, American Society for Radiation Oncology (ASTRO)
2007 AMA Women Physician Mentor Award
2002 Lifetime Achievement Award, Sister’s Network, Inc.
1999 Included in Good Housekeeping’s “Best Doctors for Breast, Lung and Colorectal Cancer”
1998-2017 Listed among Castle Connolly’s “America’s Top Doctors for Breast Cancer”
1995 ESTRO Travel Award
1995-1998 American Cancer Society Clinical Oncology Career Development Award
- MD, Duke University, 1985
- Residency, University of Pennsylvania, Radiation Oncology, 1986-89•
- Chief Resident, University of Pennsylvania, 1988-89
- Board Certification: Radiation Oncology
- (PI: Pierce), 10/1/15– 9/30/17, Breast Cancer Research Foundation: Breast Cancer Cell Sensitivity to Radiotherapy in the Presence of Targeted Therapies and Predictors of Early vs. Late Response, Role: Principal Investigator.
- (PI: Pierce), 10/1/14– 9/30/17, Breast Cancer Research Foundation: Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure following Breast Radiotherapy, Role: Principal Investigator.
- (PI: Pierce), 7/1/2010 – 3/31/18, Susan G. Komen Breast Cancer Foundation: Breast Cancer Cell Sensitivity to Radiotherapy in the Presence of Targeted Therapies, Role: Principal Investigator.
- (PI:Pierce), 2/1/11 – 1/31/18, Michigan Blue Cross Blue Shield: The Michigan Radiation Oncology Quality Consortium, Role: Principal Investigator, Director.
Selected from 138 publications
- Pierce L, Phillips K, Griffith K, Buys S, Gaffney D, Moran M, Haffty B, Ben-David M, Kaufman B, Merajver S, Balmaña J, Kierovitz A, Domchek S. Local therapy in BRCA1 and BRCA 2 mutation carriers with operable breast cancer: Comparison of breast conservation and mastectomy. Br Can Res Treat. 121(2):389-398, 2010. PMC2936479.
- Feng F, Speers C, Liu M, Jackson W, Moon D, Rinkinen J, Wilder-Romans K, Jagsi R, Pierce L. Targeted radiosensitization with PARP1 inhibition: Optimization of therapy and identification of biomarkers of response in breast cancer. Br Can Res Treat. 147(1):81-94, 2014. PMID25104443.
- EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, Correa C,Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 383(9935):2127-35, 2014. doi: 10.1016/S0140-6736(14)60488-8. PMID:24656685
- Speers C, Zhao S, Liu M, Bartelink H, Pierce LJ, Feng F. Development and validation of a novel radiosensitivity signature in human breast cancer. Clin Can Res. 21(16):3667-77, 2015. doi:10.1158/1078-0432.CCR-14-2898. PMID:25904749
- Jagsi R, Griffith K, Hayman J, Boike T, Walker E, Nurushev T, Grills I, Moran J, Feng M, Hayman J, Pierce LJ. Differences in the acute toxic effects of breast radiotherapy by fractionation schedule: Comparative analysis of physician-assesses and patient-reported outcomes in a large multicenter cohort. JAMA Oncol. 1(7):918-930, 2015.